SIGHT SCIENCES INC (SGHT)
US82657M1053 - Common Stock
We assign a fundamental rating of 3 out of 10 to SGHT. SGHT was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of SGHT is average, but there are quite some concerns on its profitability. SGHT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SGHT has reported negative net income.
In the past year SGHT has reported a negative cash flow from operations.
In the past 5 years SGHT always reported negative net income.
SGHT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -35.19%, SGHT is in line with its industry, outperforming 41.15% of the companies in the same industry.
Looking at the Return On Equity, with a value of -50.13%, SGHT is in line with its industry, outperforming 48.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.19% | ||
| ROE | -50.13% | ||
| ROIC | N/A |
ROA(3y)-32.09%
ROA(5y)-45.64%
ROE(3y)-42.4%
ROE(5y)-103.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SGHT's Gross Margin of 85.73% is amongst the best of the industry. SGHT outperforms 95.31% of its industry peers.
SGHT's Gross Margin has improved in the last couple of years.
SGHT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.57%
GM growth 5Y4.37%
2. Health
2.1 Basic Checks
SGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SGHT has more shares outstanding
The number of shares outstanding for SGHT has been increased compared to 5 years ago.
The debt/assets ratio for SGHT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.85 indicates that SGHT is not a great score, but indicates only limited risk for bankruptcy at the moment.
SGHT has a Altman-Z score (1.85) which is in line with its industry peers.
SGHT has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
SGHT's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. SGHT outperforms 45.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.85 |
ROIC/WACCN/A
WACC10.38%
2.3 Liquidity
SGHT has a Current Ratio of 13.01. This indicates that SGHT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.01, SGHT belongs to the best of the industry, outperforming 96.35% of the companies in the same industry.
SGHT has a Quick Ratio of 12.42. This indicates that SGHT is financially healthy and has no problem in meeting its short term obligations.
SGHT has a Quick ratio of 12.42. This is amongst the best in the industry. SGHT outperforms 96.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.01 | ||
| Quick Ratio | 12.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.53% over the past year.
The Revenue has grown by 8.27% in the past year. This is quite good.
SGHT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 60.84% yearly.
EPS 1Y (TTM)32.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.71%
Revenue 1Y (TTM)8.27%
Revenue growth 3Y43.14%
Revenue growth 5Y60.84%
Sales Q2Q%2.34%
3.2 Future
The Earnings Per Share is expected to grow by 15.89% on average over the next years. This is quite good.
SGHT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.01% yearly.
EPS Next Y7.31%
EPS Next 2Y12.29%
EPS Next 3Y15.89%
EPS Next 5YN/A
Revenue Next Year3.3%
Revenue Next 2Y7.77%
Revenue Next 3Y10.01%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SGHT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGHT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SGHT's earnings are expected to grow with 15.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.29%
EPS Next 3Y15.89%
5. Dividend
5.1 Amount
No dividends for SGHT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SIGHT SCIENCES INC
NASDAQ:SGHT (5/31/2024, 7:05:33 PM)
After market: 6.56 0 (0%)6.56
+0.04 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap326.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.19% | ||
| ROE | -50.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.01 | ||
| Quick Ratio | 12.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)32.53%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y7.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.27%
Revenue growth 3Y43.14%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y